ArticleFrontiers in pharmacology2022
Design and Characterization of Paclitaxel-Loaded Polymeric Nanoparticles Decorated With Trastuzumab for the Effective Treatment of Breast Cancer.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 85 citations in OpenAlex.
- Development of an Anticancer Fungal Paclitaxel-Loaded Hydrogel System via 3D Bioprinting: A Next-Generation Biomedical Platform.ACS omega · 2026Article
- Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model.International journal of pharmaceutics · 2026Article
- Enhancement of tobramycin and amikacin activities by co-encapsulation in liposomal-thymoquinone formulation: antibacterial, antibiofilm, and cytocompatibility study.Therapeutic delivery · 2026Article
- Dual-Action Theranostic Nanoparticles Delivering Toll-Like Receptor 2 Inhibitors and Chemotherapy Target Breast Cancer Cells and the Tumor Microenvironment.International journal of nanomedicine · 2026Article
- In-vitro and in-silico study to assess anti breast cancer potential of N-tosyl-indole based hydrazones.Scientific reports · 2025Article
- Anticancer Activity of Paclitaxel-Loaded Mesoporous Silica Nanoparticles in B16F10 Melanoma-Bearing Mice.Pharmaceutics · 2025Article
- Fagonia indica extract encapsulated in PLGA nanocarriers demonstrated enhanced therapeutic efficacy through improved intracellular uptake of photoactive metabolites.Scientific reports · 2025Article
- Article
- Synergistic anticancer activity of resveratrol-loaded polymeric nanoparticles and sunitinib in colorectal cancer treatment.Royal Society open science · 2025Article
- Exploring the effects of paclitaxel-loaded zein nanoparticles on human ovarian carcinoma cells.Scientific reports · 2025Article
- Design, synthesis,RSC advances · 2025Article
- Nanoparticles as Novel Drug Delivery Systems for Cancer Treatment: Current Status and Future Perspectives.Current pharmaceutical design · 2025Review
- Development of cellular models expressing cynomolgus (Frontiers in pharmacology · 2025Article
- Nanotechnology-Driven Treatment Strategies for Breast Cancer: Recent Advances and Innovations.Oncology research · 2025Review
- Encapsulation of Curcumin and Gemcitabine: Cytotoxic Effect and Mechanisms of Death in Lung Cancer.Advances in pharmacological and pharmaceutical sciences · 2025Article
- Enhanced Delivery and Potency of Chemotherapeutics in Melanoma Treatment via Magnetite Nanobioconjugates.ACS omega · 2024Article
- Review
- Combination chemotherapy via poloxamer 188 surface-modified PLGA nanoparticles that traverse the blood-brain-barrier in a glioblastoma model.Scientific reports · 2024Article
- Identification of small molecular inhibitors of SIRT3 by computational and biochemical approaches a potential target of breast cancer.Scientific reports · 2024Article
- Colloidal and Biological Characterization of Dual Drug-Loaded Smart Micellar Systems.Polymers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to design and formulate an antibody-mediated targeted, biodegradable polymeric drug delivery system releasing drug in a controlled manner to achieve a therapeutic goal for the effective treatment of breast cancer. Antibody-mediated paclitaxel-loaded PLGA polymeric nanoformulations were prepared by the solvent evaporation method using different experimental parameters and compatibility studies. The optimized formulations were selected for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.